Upadhyay, Navneet
Eli Lilly (United States)
3 papers on CoChatORCID 0000-0003-3776-9596
Most cited papers
- Verified
Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial
Borlaug, B. A., Zile, M. R., Kramer, C. M., Baum, S. J., Hurt, K., Litwin, S. E., Murakami, M., Ou, Y., Upadhyay, N., & Packer, M. (2025) · Nature Medicine
Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors
Cited by 166
- Verified
Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial
Mamas, M. A., Bays, H., Li, R., Upadhyay, N., Irani, T., Senyucel, C., Dunn, J. P., & Liu-Seifert, H. (2025) · European Heart Journal Open
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 24
- Verified
Reversibility of Psychotropic Medication Induced Weight Gain Among Children and Adolescents With Bipolar Disorders
Upadhyay, N., Patel, A., Chan, W., Aparasu, R. R., Ochoa-Perez, M., Sherer, J. T., Sanyal, S., & Chen, H. (2019) · Psychiatry Research
Bipolar Disorder and TreatmentSchizophrenia research and treatment
Cited by 11
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free